5,611
Views
95
CrossRef citations to date
0
Altmetric
Original Research Articles

Efficacy of contraceptive methods: A review of the literature

, &
Pages 4-16 | Published online: 08 Feb 2010
 

Abstract

Objectives To provide a comprehensive and objective summary of contraceptive failure rates for a variety of methods based on a systematic review of the literature.

Methods Medline and Embase were searched using the Ovid interface from January 1990 to February 2008, as well as the reference lists of published articles, to identify studies reporting contraceptive efficacy as a Pearl Index or life-table estimate. Reports that recruited less than 400 subjects per study group and those covering less than six cycles/six months were excluded. In addition, unlicensed products or those not internationally available, emergency contraception, and vasectomy studies were excluded.

Results Information was identified and extracted from 139 studies. One-year Pearl Indices reported for short-acting user-dependent hormonal methods were generally less than 2.5. Gross life-table rates for long-acting hormonal methods (implants and the levonorgestrel releasing-intrauterine system [LNG-IUS]) generally ranged between 0–0.6 per 100 at one year, but wider ranges (0.1–1.5 per 100) were observed for the copper intrauterine devices (0.1–1.4 per 100 for Cu-IUDs with surface area ≥300 mmCitation and 0.6–1.5 per 100 for those with surface area <300 mmCitation). Barrier and natural methods were the least effective.

Conclusions Our review broadly confirms the hierarchy of contraceptive effectiveness in descending order as: (1) female sterilisation, long-acting hormonal contraceptives (LNG-IUS and implants); (2) Cu-IUDs with ≥300 mmCitation surface area; (3) Cu-IUDs with <300 mmCitation surface area and short-acting hormonal contraceptives (injectables, oral contraceptives, the patch and vaginal ring), and (4) barrier methods and natural methods.

Declaration of interest: Dr Mansour has received support to undertake research, attend clinical meetings and scientific advisory boards for Bayer Schering Pharma AG, Dr Gemzell-Danielsson has participated on scientific advisory boards for both Bayer Schering Pharma AG and Organon, and Dr Pirjo Inki is an employee of Bayer Schering Pharma AG.

Editorial assistance for the development of this manuscript was provided by Richard Glover of Wolters Kluwer, with the financial support of Bayer Schering Pharma AG.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.